Eli Lilly and Company (LLY)vsPetroleo Brasileiro Petrobras SA ADR (PBR)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
PBR
Petroleo Brasileiro Petrobras SA ADR
$17.75
+0.77%
ENERGY · Cap: $117.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Petroleo Brasileiro Petrobras SA ADR generates 589% more annual revenue ($498.09B vs $72.25B). LLY leads profitability with a 35.0% profit margin vs 21.6%. LLY appears more attractively valued with a PEG of 1.45. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PBR
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+89.6%
Fair Value
$176.60
Current Price
$17.75
$158.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 32.0%
Large-cap with strong market position
Every $100 of equity generates 24 in profit
Keeps 22 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.4% revenue growth
Expensive relative to growth rate
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PBR
The strongest argument for PBR centers on P/E Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 21.6% and operating margin at 32.0%.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : PBR
The primary concerns for PBR are Revenue Growth, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while PBR is a value play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
PBR generates stronger free cash flow (3.3B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 66/100), backed by strong 35.0% margins and 55.5% revenue growth. PBR offers better value entry with a 89.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Petroleo Brasileiro Petrobras SA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Petrleo Brasileiro SA - Petrobras produces and sells oil and gas in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?